Table 3. Inter-visit difference in group B (placebo-montelukast group).
Phase I | P value | Phase II | P value | |||
---|---|---|---|---|---|---|
Visit 2 (Week 0) | Visit 4 (Week 8) | Visit 5 (Week 10) | Visit 7 (Week 18) | |||
SCORAD index | 34.7±13.7 | 30.5±12.5 | 0.31 | 28.0±14.1 | 25.9±11.9 | 0.60 |
U-LTE4 (pg/mL) | 430.4±428.0 | 438.8±420.6 | 0.95 | 552.0±427.4 | 461.7±433.6 | 0.50 |
U-EDN (ng/mL) | 755.2±787.7 | 584.8±722.7 | 0.47 | 671.3±657.1 | 981.3±788.1 | 0.17 |
SCORAD, SCORing Atopic Dermatitis; U-LTE4, Urine leukotriene E4; U-EDN, Urine eosinophil-derived neurotoxin.